- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03959046
GIST in Hematopoietic Stem Cell Transplantation/Bone Marrow Transplantation
Giving Information Strategically and Transparently in Hematopoietic Stem Cell Transplantation/Bone Marrow Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hematopoietic stem cell/bone marrow transplantation (HSCT/BMT) is a high-risk, complicated procedure that is poorly understood by patients, posing a challenge for informed decision-making. One study found that 69.7% of patients needed more information about HSCT to make an informed decision. Furthermore, for most patients who seek HSCT/BMT as treatment, transplantation is the only viable option for long-term, disease-free survival. In light of limited options, it is often assumed that patients will choose to undergo transplantation by default, which might undermine efforts to ensure that patients are fully informed. Given the context in which the decision to undergo transplantation are made, there is a clear and present need to ensure that patients are properly informed about HSCT/BMT.
Unfortunately, this need does not seem to be adequately met. For example, studies have shown that patients tend not to remember rates of risks and complications. One study found that after completing HSCT, patients recalled a mortality risk rate lower than those provided by physicians at their initial consultation (20% vs. 30%, respectively). Findings such as this highlight the need to improve the informed consent process for patients confronting the decision to undergo HSCT/BMT.
The present study aims to improve the informed consent process by proposing a new approach to patient-physician communication, called Giving Information Simply and Transparently (GIST), that will train physicians to speak more understandably, with the goal of improving patients understanding of the procedures they intend to pursue. This approach is based upon Dr. Valerie Reyna's Fuzzy Trace Theory which posits that patients focus on the bottom-line gist of information when formulating their treatment preferences. Patient understanding will be tested via assessments administered after their consultation visit, 30 days after initiation of chemotherapy, and 100 days after initiation of chemotherapy.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Weill Cornell Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- acute myeloid leukemia with high or intermediate risk in first complete remission acute myeloid leukemia OR myelodysplastic syndrome beyond first remission chronic myeloid leukemia with accelerated phase or blast crisis acute lymphocytic leukemia Myeloma lymphoma with a sensitive relapse lymphoma with a resistant relapse first time undergoing consultation at this institution's HSCT/BMT program Fluent in English
Exclusion Criteria:
- Cognitively impaired
- Not fluent in English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GIST
GIST is an alternative way of speaking to patients.
In order for patients to get the "gist," Hematologists will ensure that patients walk away from their initial consultation understanding: why they are candidates for bone marrow transplant (BMT), what the process for BMT is, and the major risks involved.
|
The GIST intervention will train physicians in an alternative way of communicating with their patients.
|
No Intervention: Usual Care
These are physician and patient participants that will communicate in their normal, unchanged way.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from 1 week post baseline understanding at 3 months
Time Frame: 1 week, 1 month and 3 months from baseline (T2, T3, and T4)
|
Evidence that patients assigned to physicians trained in the GIST approach will have improved recall of information and be able to answer more questions correctly about HSCT/BMT than those assigned to care as usual.
The researchers have developed a brief assessment of patient knowledge of: a) why the participants are a candidate for HSCT/BMT; b) what the procedure involves; c) risks and benefits posed by HSCT/BMT.
The assessment will consist of multiple choice questions, with one fill-in-the-diagram question.
The high score is 90, and the low score is 18.
A score of 90 means that the participant fully understands the three points listed above.
A score of 18 means that the participant has little to no understanding of the three points listed above.
|
1 week, 1 month and 3 months from baseline (T2, T3, and T4)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient's emotional acceptance of their illness
Time Frame: 1 week, 1 month and 3 months from baseline (T2, T3, and T4)
|
We will use 5 relevant items from the validated PEACE scale which asks patients about how accepting they are of their illness.
Responses include "not at all", "to a slight extent", "to some extent", "to a large extent".
The questionnaire is composed of two combined subscales: a 2-item "Peaceful Acceptance" and a 3-item "Struggle with Illness" subscale.
Both subscales are associated with patients' self-reported peacefulness "Struggle with Illness" scores are associated with acknowledgement of cognitive terminal illness.
The low score for this scale is 5 (indicating little acceptance) and the high score is 20 (indicating high acceptance).
|
1 week, 1 month and 3 months from baseline (T2, T3, and T4)
|
Patient's emotional acceptance of their lives
Time Frame: 1 week, 1 month and 3 months from baseline (T2, T3, and T4)
|
The MEPSI is an 8 item questionnaire (shortened from the original) that asks patients to respond to phrases regarding how they view their lives.
Responses include "not at all", "to a slight extent", "to some extent", "to a large extent".
The questionnaire is composed of two combined subscales: a 4 item "Positive" subscale and a 4-item "Negative" subscale.
The low score for this scale is 8 (indicating little acceptance) and the high score is 32 (indicating high acceptance).
|
1 week, 1 month and 3 months from baseline (T2, T3, and T4)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Human Connection (THC) Scale
Time Frame: One week, one month and three months from baseline (T2, T3, and T4)
|
The effect on changing physician communication on patient-physician relationships will be measured by The Human Connection (THC) scale.
THC is a validated 16 item questionnaire that measures the extent to which patients felt a sense of mutual understanding, caring, and trust with their physicians.
Patients are asked to circle one of four phrases that answers the questions.
The 16-item THC questionnaire was internally consistent (Cronbach's α =.90) and valid, based on its expected positive association with emotional acceptance of the terminal illness (r=.31,
P<.0001).
Scores range from 16 (the lowest score, indicating a weak therapeutic alliance) and 64 (the high score, indicating a strong therapeutic alliance).
|
One week, one month and three months from baseline (T2, T3, and T4)
|
Levels of anxiety and depression in patients
Time Frame: 1 week, 1 month and 3 months from baseline (T2, T3, and T4)
|
levels of anxiety and depression will be assessed via the Hospital Anxiety and Depression Scale (HADS).
It is a verified and brief 14-item tool that asks patients to choose a 1 out of 4 possible responses to each statement, with each response being assigned to a score of 0, 1, 2, or 3. 7 statements correspond to measuring depression, while the other 7 corresponding to measuring anxiety.
Score of 0-7 indicates that the patient is "normal; 8-10 indicates the patient is borderline; and 11-21 indicates abnormal.
|
1 week, 1 month and 3 months from baseline (T2, T3, and T4)
|
Health Literacy in older adults compared to younger adults
Time Frame: Baseline, 1 week, 1 month and 3 months from baseline (T1, T2, T3, and T4)
|
The researchers have developed a brief assessment of patient knowledge of: a) why the participants are a candidate for HSCT/BMT; b) what the procedure involves; c) risks and benefits posed by HSCT/BMT.
The assessment will consist of multiple choice questions, with one fill-in-the-diagram question.
The high score is 90, and the low score is 18.
A score of 90 means that the participant fully understands the three points listed above.
A score of 18 means that the participant has little to no understanding of the three points listed above.
We will compare the scores of older adults (>65) to younger adults (<65) to see which group overall has a higher score.
|
Baseline, 1 week, 1 month and 3 months from baseline (T1, T2, T3, and T4)
|
Assessment of patient's health literacy
Time Frame: 1 week, 1 month and 3 months from baseline (T2, T3, and T4)
|
Assessment of patient's health literacy via Rapid Estimate of Adult Literacy in Medicine - Short Form(REALM-SF) will be administered to control for variable health literacy.
REALM-SF is a validated and brief literacy assessment tool of a patient's health literacy.
REALM-SF consists of a list of 7 medically related words that is shown to the patient.
Patients are asked to read the words out loud in order of the list, with the option of saying "pass" when they encounter a word that they do not recognize, allowing them to move onto the next word; alternatively, patients taking longer than 5 seconds to read a word will be told to move onto the next word by the interviewer.
Each word a patient recognizes is a point that is used to score the assessment.
0 points is equivalent to a 3rd grade reading level, 1-3 points is equivalent to a 4th to 6th grade level, 4-6 points is equivalent to a 7th to 8th grade level, and 7 points is equivalent to at least a high school level.
|
1 week, 1 month and 3 months from baseline (T2, T3, and T4)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Holly G Prigerson, PhD, Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 1807019470
- 5R35CA197730 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on GIST
-
Sunnaas Rehabilitation HospitalUniversity of OsloCompleted
-
Weill Medical College of Cornell UniversityNational Institute of Nursing Research (NINR)CompletedCritical Illness | Communication | OncologyUnited States
-
Weill Medical College of Cornell UniversityNational Institute of Nursing Research (NINR)CompletedCritical Illness | Communication | OncologyUnited States
-
Georgetown UniversityVirginia Commonwealth University; Cornell UniversityCompletedHereditary Breast and Ovarian CancerUnited States
-
M.D. Anderson Cancer CenterNovartis PharmaceuticalsCompleted
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
The University of Texas at DallasUniversity of TexasCompletedBipolar Disorder | Cognitive Ability, General
-
M.D. Anderson Cancer CenterNovartisUnknown
-
Anderson Clinical ResearchLigand PharmaceuticalsCompletedHIV Infections | Sarcoma, Kaposi
-
George Washington UniversityCompleted